Affimed N.V (AFMD) a clinical-stage immuno-oncology company, committed to giving patients back their innate ability to fight cancer, has a couple of upcoming clinical trial events this quarter.
The company has 3 drug candidates in clinical testing - AFM24, Acimtamig (AFM13) and AFM28.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com